(PRNewswire) A panel of experts has recommended changes to the guidelines used to determine treatment via intrathecal administration for patients suffering from severe chronic pain. The 2011 Polyanalgesic Consensus Conference (PACC) brought together a group of national leaders in chronic pain management for the purpose of updating their current algorithm to standardize decision-making among providers and improving the technical quality of care in chronic pain.
The 2011 PACC guidelines for management of nociceptive and neuropathic chronic pain by intrathecal drug delivery recommended ziconotide, among other drugs, as a first-line intrathecal treatment. The panel recognized that ziconotide should be titrated in a low and slow manner. Ziconotide was also recommended by the 2011 group as the preferred option for intrathecal administration compared to opioids when there is a concern for recurrent granuloma.
The expert panel recommendation was based on an extensive literature search and an expansive survey with more than 15,000 clinicians worldwide since the last update in 2007. The panel also reviewed changes in the FDA status of medications and their combined clinical expertise to inform their recommendations.